Background and Aims: Acute exacerbations of bronchiectasis impose significant morbidity on patients, and contribute to a large burden in healthcare costs. Length of hospitalization stay (LOS) is an important component of this cost. Clinical pathways (CP) have been shown to be effective in reducing LOS in other respiratory conditions such as chronic obstructive pulmonary disease and asthma. However, CP has not been established to optimise outcomes in bronchiectasis. The objective of this study was to determine the effect of implementing CP on the management of patients with acute exacerbations of bronchiectasis.
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Methods: A retrospective analysis on all adult patients admitted with acute exacerbations of bronchiectasis between 2015 and 2017 was conducted. Demography, LOS, and co-morbidities were established. Patients were divided into (1) CP group, and (2) non-CP group. The primary endpoint was LOS, and the secondary endpoint was the event rate of recurrent hospitalisation with bronchiectasis exacerbation within 30 days of discharge.
Results: A total of 594 patients were identified with 242 patients in CP group and 352 patients in non-CP group. Age, gender, body mass index, smoking history and sputum microbiology were similar in both groups. The median (IQR) LOS was significantly shorter in CP than non-CP (5.5 (4-7) days versus. 6 (4-8) days, P = 0.028). There was no significant difference on 30 days readmission rate (P = 0.2), and time to readmission (P = 0.5).
Conclusion:
Our study demonstrated that implementation of a CP specifically designed for patients with acute exacerbations of bronchiectasis had the potential of reducing hospital LOS. Background and Aims: Advanced oesophageal cancer patients with airway involvement had poor prognosis. Self-expandable metallic stents (SEMSs) implantation via bronchoscopy can immediately relieve airway stenosis and offer the opportunity of survival improvement. The purpose of this study was to determine the factors that predict survival in patients with airway involvement due to advanced oesophageal cancer after SEMSs implantation.
Bronchoscopy and Interventional
Methods: We conducted a retrospective study, from February 2007 to July 2013, in a university hospital. A total 42 advanced oesophageal cancer patients with airway involvement were included during this period.
These patients underwent flexible bronchoscopy with electrosurgery and SEMSs implantation under bronchoscopic visualization and local anaesthesia without fluoroscopic guidance throughout the procedure.
Results:
The total 42 patients were included in analysis. Acute respiratory failure was found in 14 patients (33.3%). After SEMSs implantation, additional anti-cancer therapy was performed in 28 patients (66.7%). The median survivals after procedure was 83 days. Longer survival was seen in subjects with further anti-cancer therapy (HR, 0.146; CI, 0.06-0.34; P < 0.001). Persistent pneumonia and poor PFS may be potential factors that make patients without further therapy. Patients with anti-cancer therapy before procedure (HR, 3.429; CI, 1.54-7.60; P = 0.002) and acute respiratory failure (HR, 5.224; CI, 2.23-12.26; P < 0.001) had poorer survival. Patients with the residual diameters of obstructive trachea < 0.77 cm had high risk of acute respiratory failure.
Conclusion: SEMSs insertion with flexible bronchoscopy provide patients with airway involvement by advanced oesophageal cancer an opportunity of survival improvement. The patients with anti-cancer therapy before procedure and acute respiratory failure had poor prognosis. ARF easily occurred if the residual diameters of obstructive trachea was less than 0.77 cm. On the contrast, available post airway stenting therapy improved these patient's survival. Background and Aims: Pulmonary nodules are a common but difficult issue for physicians as most identified on imaging are benign but those identified early that are cancerous are potentially curable. Multiple diagnostic options are available but each technique has differences in diagnostic yield and complication rates with no established gold standard. With the recent advent of electromagnetic navigation (EMN), a combined bronchoscopic and transthoracic approach is now feasible in a single, staged procedure. Here, we present the study design and initial nodule characteristics for a single-arm trial evaluating a staged approach for the diagnosis of pulmonary nodules. (NCT03338049)
Methods: Participants with 1-3 cm, intermediate to high-risk pulmonary nodules will undergo a staged approach with endobronchial ultrasound (EBUS) followed by EMN-bronchoscopy (ENB), then EMNtransthoracic biopsy (EMN-TTNA) with the procedure terminated at any stage after a diagnosis is made via rapid onsite cytopathology. (Figure 1 ) We aim to recruit 150 EMN participants from eight academic and community settings in the United States to show significant improvements over other historic bronchoscopic guided techniques. The primary outcome is overall diagnostic yield of the staged approach.
